SpyGlass Pharma, Inc. Common Stock (SGP) Stock Price
SGPStock
$26.60
Market Cap$889.72M
P/E—
PEG Ratio—
Div yield—
Beta1.23
SGP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-19.11%
Price vs S&P 500 (4W)18.41%
VGM Score67.28
SGP Earnings Surprise History
Q1 26-0.69est. -0.36
Q2 26-0.59est. -0.55
SGP Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.44
4.44
4.44
4.44
Industry Peers — Surgical & Medical Instruments(140)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SGPSpyGlass Pharma, Inc. Common Stock | — | — | B | $26.60 |
| SYKStryker Corporation | C | B | C | $330.59 |
| MMM3M Company | C | D | B | $179.37 |
| BSXBoston Scientific Corp. | C | B | D | $49.86 |
| BDXBecton, Dickinson and Co. | B | D | B | $189.78 |
| MDLNMedline Inc. Class A common stock | C | D | C | $35.64 |
| RMDResMed Inc. | C | B | C | $236.59 |
| DXCMDexCom, Inc. | D | B | B | $89.16 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $348.48 |
| SOLVSolventum Corporation | C | C | B | $91.61 |
| BAXBaxter International Inc. | B | D | B | $26.29 |
About SpyGlass Pharma, Inc. Common Stock
SpyGlass Pharma is a late-stage biopharmaceutical company developing long-acting drug delivery systems for chronic eye conditions. The company is advancing two programs: the BIM-IOL System, which delivers glaucoma treatment during cataract surgery, and the BIM-DRS for glaucoma patients not undergoing surgery. Both programs leverage sustained drug delivery of approved medicines to address unmet treatment needs in ophthalmology.